Biomind Labs Inc. announced that a third Phase II clinical trial for its BMND08 candidate based on 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment has been approved by the Argentinian Institutional Review Board.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.11 USD | -.--% | -.--% | +10.00% |
1st Jan change | Capi. | |
---|---|---|
+10.00% | 8.22M | |
+24.98% | 46.71B | |
+48.83% | 41.8B | |
-0.97% | 41.52B | |
-5.86% | 29.55B | |
+10.33% | 25.78B | |
-20.96% | 19.26B | |
+1.90% | 12.14B | |
-2.92% | 12.08B | |
+27.82% | 11.98B |
- Stock Market
- Equities
- BMND.F Stock
- News Biomind Labs Inc.
- Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease